Abstract
During the past few years, Epithelial-Mesenchymal Transition (EMT) has emerged as one of the most hot spots in clinical research. Its existence in human tumors can form the basis for explaining characteristics of cancer progression and metastasis, as well as certain cases of drug resistance and relapses after treatment. These cellular responses are tightly regulated by intracellular signaling pathways evoked by humoral factors that include growth factors, chemokines and cytokines. Indeed, several gene regulatory programs known to promote EMT during development have recently been discovered to play key roles in cancer progression. A deeper understanding of the cellular and molecular basis of these different programs should aid in both the development of better diagnosis methods, as well as of specific treatments for invasive cancer. In this review we set out to summarize recent novel insights into the molecular players underlying EMT and its relation with cancer progression and metastasis.
Keywords: Cancer, EMT, invasion, metastasis, MMP, NF-B, RTKs, TGF-, humoral factors, molecular players underlying EMT, epithelial cells phenotype, epithelial genes, cell-matrix interactions, pathological processes, cell surface E-cadherin
Current Pharmaceutical Biotechnology
Title: Epithelial-Mesenchymal Transition: Implications in Cancer Progression and Metastasis
Volume: 12 Issue: 11
Author(s): L. R. Gomes, L. F. Terra, M. C. Sogayar and L. Labriola
Affiliation:
Keywords: Cancer, EMT, invasion, metastasis, MMP, NF-B, RTKs, TGF-, humoral factors, molecular players underlying EMT, epithelial cells phenotype, epithelial genes, cell-matrix interactions, pathological processes, cell surface E-cadherin
Abstract: During the past few years, Epithelial-Mesenchymal Transition (EMT) has emerged as one of the most hot spots in clinical research. Its existence in human tumors can form the basis for explaining characteristics of cancer progression and metastasis, as well as certain cases of drug resistance and relapses after treatment. These cellular responses are tightly regulated by intracellular signaling pathways evoked by humoral factors that include growth factors, chemokines and cytokines. Indeed, several gene regulatory programs known to promote EMT during development have recently been discovered to play key roles in cancer progression. A deeper understanding of the cellular and molecular basis of these different programs should aid in both the development of better diagnosis methods, as well as of specific treatments for invasive cancer. In this review we set out to summarize recent novel insights into the molecular players underlying EMT and its relation with cancer progression and metastasis.
Export Options
About this article
Cite this article as:
R. Gomes L., F. Terra L., C. Sogayar M. and Labriola L., Epithelial-Mesenchymal Transition: Implications in Cancer Progression and Metastasis, Current Pharmaceutical Biotechnology 2011; 12 (11) . https://dx.doi.org/10.2174/138920111798377102
DOI https://dx.doi.org/10.2174/138920111798377102 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Lipoprotein-Related and Apolipoprotein-Mediated Delivery Systems for Drug Targeting and Imaging
Current Medicinal Chemistry Brain Segmentation Using Deep Neural Networks
International Journal of Sensors, Wireless Communications and Control Oligonucleotides as Anticancer Agents: From the Benchside to the Clinic and Beyond
Current Pharmaceutical Design A Systematic Review of Genes Involved in the Inverse Resistance Relationship Between Cisplatin and Paclitaxel Chemotherapy: Role of BRCA1
Current Cancer Drug Targets miR-149 as a Potential Molecular Target for Cancer
Current Medicinal Chemistry Combination of Phytochemicals as Adjuvants for Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Cancer Stem Cells in Prostate Cancer Chemoresistance
Current Cancer Drug Targets Editorial (Thematic Issue: Advances with microRNAs in Tumorigenesis and Cancer Therapy)
Current Pharmaceutical Design Tip60: Main Functions and Its Inhibitors
Mini-Reviews in Medicinal Chemistry Base Excision Repair: Contribution to Tumorigenesis and Target in Anticancer Treatment Paradigms
Current Medicinal Chemistry Targeting RANK/RANKL in the Treatment of Solid Tumours and Myeloma
Current Pharmaceutical Design 9th International Meeting on Metabotropic Gglutamate Receptors (Taormina, Sicily, October 1-6, 2017).
Current Neuropharmacology Anti-Carcinogenic Effects of Carnosol-An Updated Review
Current Drug Discovery Technologies Manipulation and Engineering of Metabolic and Biosynthetic Pathway of Plant Polyphenols
Current Pharmaceutical Design Peptide modules for overcoming barriers of nucleic acids transport to cells
Current Topics in Medicinal Chemistry Targetin g Human Tel omerase by Antisens e Oligonucleotides and Ribozymes
Current Medicinal Chemistry - Anti-Cancer Agents Palliative Care in High and Low Resource Countries
Current Pediatric Reviews Discovery and Development of Natural Products and their Derivatives as Photosensitizers for Photodynamic Therapy
Current Medicinal Chemistry How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization
Mini-Reviews in Medicinal Chemistry Cellular Senescence in the Development and Treatment of Cancer
Current Pharmaceutical Design